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Abstract 
Fabry disease is an X-linked inherited lysosomal storage disorder caused by mutations in the 
gene encoding α-galactosidase A (GLA). Once it was thought to affect only hemizygous 
males. Over the last fifteen years, research has shown that most females carrying mutated 
allele also develop symptoms, demonstrating a wide range of disease severity, from a 
virtually asymptomatic to more classical profile, with cardiac, renal, and cerebrovascular 
manifestations. This variable expression in females is thought to be influenced by the process 
of X-chromosome inactivation (XCI). The aim of this study was to assess severity of the 
clinical phenotype, to analyze XCI patterns, and to estimate their effect on disease 
manifestation in twelve female Fabry disease patients from five unrelated Polish families. Our 
analyses revealed that patients presented with the broad range of disease expression - from 
mild to severe, and their clinical involvement did not correlate with XCI profiles. Female 
carriers of the mutation in the GLA gene with the random XCI may present with the wide 
range of disease signs and symptoms. Thus, XCI is not a main factor in the phenotype 
variability of Fabry disease manifestation in heterozygous females. 
Keywords: FOS-MSSI; heterozygotes; MSSI; severity score; XCI. 
Abbreviations list: 
AR - androgen receptor 
DS3 - Fabry disease severity scoring system 
FOS - Fabry Outcome Survey 
FOS-MSSI - Fabry Outcome Survey Mainz Severity Score Index 
α-GAL A - α-galactosidase A 
Gb3 – globotriaosylceramide 
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GL3 - globotriaosylceramide 
GLA - α-galactosidase A 
lyso-Gb3 - globotriaosylsphingosine 
MSSI - Mainz Severity Score Index 
XCI - X-chromosome inactivation 
 
1. Introduction 
Fabry disease (OMIM #301500), also known as Anderson-Fabry disease or angiokeratoma 
corporis diffusum, is a lysosomal storage disorder caused by a deficiency of α-galactosidase A 
(α-GAL A, GLA), an enzyme required for the degradation of globotriaosylceramide (Gb3, 
GL3). The GLA gene coding for α-GAL A maps to Xq22.1 (locus MIM number: *300644). 
The earliest symptoms observed in patients with the classic form of the disorder in childhood 
and adolescence (in males earlier than in females) include neuropathic pain, vascular skin 
lesions, sweating abnormalities, characteristic ocular changes, gastrointestinal problems, 
temperature intolerance, and proteinuria (Mehta et al., 2010; Mehta and Hughes, 2002). These 
symptoms tend to worsen with age and are often followed by progressive renal failure, as well 
as cardiac disease, transient ischemic attacks, and stroke. Many male patients are additionally 
characterized by typical facial features (MacDermot et al., 2001). Compared with the general 
population of the United States in 2008, the life expectancy of patients with Fabry disease was 
reduced by 22% in males and 5.75% in females, with cardiovascular disease being the most 
common cause of death among both genders (Waldek et al., 2009). 
Historically, Fabry disease was considered to be inherited in an X-linked recessive manner, 
and affect primarily males. In the majority of X-linked recessive disorders, heterozygous 
females are usually asymptomatic carriers of the condition. Symptomatic carriers occur 
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occasionally, usually due to chromosomal rearrangements or nonrandom X-chromosome 
inactivation (XCI), as it was also described for two other X-linked lysosomal storage 
disorders, mucopolysaccharidosis type II (Kloska et al., 2011) and Danon disease (Hedberg 
Oldfors et al., 2015). However, in case of Fabry disease, most of heterozygous females are 
clinically affected, presenting with a wide spectrum of signs and symptoms. The phenotype 
variability of disease manifestation in heterozygous females is much higher than in males, 
symptoms usually occur later in life and progress slower. Disease manifestation in 
heterozygous females is hypothesized to be related to skewed X-inactivation favoring the 
mutant GLA allele. Nonetheless, previous studies evaluating the existence of skewed XCI in 
females with Fabry disease have led to ambiguous results. Some of them suggest a correlation 
between the severity of clinical involvement and XCI (Dobrovolny et al., 2005; Echevarria et 
al., 2016; Morrone et al., 2003; Redonnet-Vernhet et al., 1996), while others do not support it 
(Elstein et al., 2012; Maier et al., 2006). In order to further investigate the relationship 
between XCI patterns and severity of Fabry disease signs and symptoms in carriers, we 
examined the contribution of X-inactivation patterns to disease manifestations in a cohort of 
Polish Fabry heterozygous females. 
2. Materials and Methods  
2.1. Patients 
Twelve symptomatic heterozygous females with family history of Fabry disease from five 
unrelated Polish families were recruited for the study. At the time of recruitment in 2014-
2015 they were aged between 11 and 67 years (mean age, 40.7 years) and none of them 
received enzyme replacement therapy (ERT). Saliva samples were collected from all subjects 
using the Oragene DNA Self-Collection Kit (OG-500) and DNA was isolated according to 
the prepIT•L2P protocol (DNA Genotek Inc., Ontario, Canada). The study protocol was 
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approved by the Ethical Committee of the Regional Chamber of Physicians and written 
informed consent was obtained from the participants or parents before enrollment. 
2.2. Clinical analysis 
Clinical phenotypes of the patients were evaluated by physical examination according to four 
severity scores: a) Mainz Severity Score Index (MSSI) developed to assess the severity of 
Fabry disease and monitor its clinical course in response to enzyme replacement therapy 
(Whybra et al., 2004), b) its derivative considering data collected in the Fabry Outcome 
Survey (FOS) database, the FOS-MSSI (Whybra et al., 2006), c) the age-adjusted score that 
allows comparison of Fabry disease severity in different subgroups without age or sex 
confounding factors (Hughes et al., 2010), and d) Fabry disease severity scoring system (DS3) 
developed for easy use in the general Fabry patient population (Giannini et al., 2010). The 
analysis included general, neurological, cardiovascular and renal signs and symptoms that are 
associated with Fabry disease (Giannini et al., 2010; Whybra et al., 2006, 2004). 
2.3. GLA sequencing 
Data on GLA gene mutations identified in males with Fabry disease from families 1, 2, 4, and 
5 were available after genetic confirmation of the diagnosis. Heterozygous status in GLA gene 
in females from these families was confirmed by sequencing exons 1, 6 or 7. Fragments of the 
GLA gene were amplified using following M13-tailed primer pairs: 
exon 1: 5’-TGTAAAACGACGGCCAGTGTTCCCGTTGAGACTCTCCAGTTC-3’,  
  5’-CAGGAAACAGCTATGACCGGAAATAGGGCGGGTCAATATCAAG-3’, 
exon 6: 5’-TGTAAAACGACGGCCAGTTGATAGTAACATCAAGAGCAAGGGAAA-3’, 
  5’-CAGGAAACAGCTATGACCCCTTGTTCAAGACCCTGCGG-3’, 
exon 7: 5’-TGTAAAACGACGGCCAGTTGAATGGAGAAAAAGGTGGACAGGA-3’,
  5’-CAGGAAACAGCTATGACCCCCTTGCTCTTGATGTTACTATCAG-3’. 
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These three pairs of primers were also used to screen for mutations in exons 1, 6 or 7 in 
females II-1 and III-2 from the family 3. 
Genomic DNA (75 ng) was amplified with 1X High Fidelity PCR buffer (Invitrogen), 2 mM 
MgSO4, 200 µM of each dNTP, 0.2 µM of each primer, and 1U Platinum Taq DNA 
Polymerase High Fidelity (Invitrogen) in a total volume of 10 µl. The PCR conditions were 
94°C for 2 min (initial denaturation), followed by 35 cycles of 94°C for 15 s, 58°C for 30 s, 
and 68°C for 45 s. PCR products were purified using ExoSAP (USB Corporation) and 
sequenced by Genomed S.A., Poland. Chromatograms were analyzed using Chromas Lite 
2.1.1 (Technelysium Pty Ltd). 
2.4. X-inactivation analysis 
Patterns of X-chromosome inactivation were determined by the analysis of methylation status 
at polymorphic region of the human androgen receptor gene (AR or HUMARA) as described 
previously (Allen et al., 1992), with modifications. Genomic DNA (100 ng) was digested for 
16 hours at 37°C with 10 U of HpaII in a total volume of 10 µl. For each sample, an 
undigested control was prepared with the same amount of genomic DNA, enzyme digestion 
buffer, but without restriction enzyme. To determine the XCI pattern in the AR assay, both, 
digested and undigested samples (5 µl) were amplified with 1X Roche PCR reaction buffer 
with 1.5 mM MgCl2, 200 µM of each dNTP, 0.2 µM of each primer, and 0.75 U of Taq DNA 
Polymerase (Roche) in a total volume of 15 µl. The forward PCR primer was labeled with the 
6-FAM. The PCR conditions were 95°C for 5 min (initial denaturation) followed by 35 cycles 
of 95°C for 40 s, 62°C for 40 s, and 72°C for 40 s, with a final extension at 72°C for 7 min. 
All samples were analyzed in duplicate, and the ratios obtained were averaged. DNA of a 
female with 80:20 skewed XCI was used as a control in each assay run to assess inter-assay 
variability. PCR products were separated by capillary electrophoresis on an ABI Prism 310 
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Genetic Analyzer in denaturing conditions. Product length and peak areas were analyzed 
using Peak Scanner Software v1.0 (Applied Biosystems). The XCI pattern was classified as 
random (50:50 to 75:25) or skewed (75:25 and more). 
Complete HpaII digestion of genomic DNA prior to AR gene assay was confirmed by 
amplification of the 5’ region of the MIC2 gene (an X-linked gene that escapes X-inactivation 
and should be completely digested by methylation-sensitive HpaII enzyme) (Anderson and 
Brown, 2002; Goodfellow et al., 1988) according to a modified protocol of Wu et al. (Wu et 
al., 2014). Both, HpaII-digested and undigested samples (4 µl) were amplified with 1X 
reaction buffer with 1.5 mM MgCl2, 200 µM of each dNTP, 0.2 µM of each primer, and 0.75 
U of Taq DNA Polymerase (Roche) in a total volume of 15 µl. The PCR conditions were 
95°C for 5 min (initial denaturation), followed by 35 cycles of 95°C for 40 s, 63°C for 40 s, 
and 72°C for 40 s, with a final extension at 72°C for 7 min. PCR products were separated by 
standard agarose gel electrophoresis. 
2.5. Statistical analysis 
Pearson correlation coefficients were calculated to assess the linear relation between XCI 
pattern and clinical phenotype severity scores (MSSI, FOS-MSSI, DS3, and age-adjusted 
score), age and these scores, and age and XCI pattern. A p value of <0.05 was considered 
statistically significant. Analyses were performed using Statistica 13 (Dell Inc.). 
 
3. Results 
3.1. Clinical characteristics 
Familial relationships of the female Fabry disease participants in this study are outlined in 
Figure 1. Although the grandmother from the family 1 was not tested by us, as the mother of 
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three affected daughters, she is an obligate heterozygote. Moreover, her medical history 
shows that she was also symptomatic - she developed cerebrovascular disease and died of 
stroke at the age of 42. Heterozygous status of the woman III-1 from family 3 (not included in 
this analysis due to her moving abroad) was confirmed by independent commercial 
laboratories. 
Table 1 provides the age at diagnosis and first manifestations of Fabry disease in the analyzed 
group of females. The mean age at symptom onset was 14 years (range: 5-35 years). Except 
for the two youngest patients, who were diagnosed pre-symptomatically, all experienced 
delay in diagnosis (mean: 21, range: 8-37 years). Eight of eleven females (one did not specify 
early symptoms of the disease) reported severe pain in the extremities (acroparesthesia) as the 
first manifestation of the disease. 
Analyzed females with Fabry disease had varied symptoms without any organ- or tissue-
specific expression. The severity of disease manifestations was assessed by MSSI and FOS-
MSSI scores and their sub-scores: general, neurological, cardiovascular, and renal, as well as 
DS3 (Table 2). Using MSSI scores, all three levels of severity were observed, with 3 patients 
expressing mild, 7 moderate, and 2 severe phenotype. The total FOS-MSSI scores obtained 
for our patients shifted the severity classification of 2 patients with severe phenotype into 
moderate, and 3 moderate into mild. This inconsistency in severity classification results from 
the different weighting of Fabry disease signs and symptoms applied in calculation of both 
severity indices (according to the contribution to the morbidity of the disease in MSSI and 
according to the data collected in FOS in FOS-MSSI) and the fact that FOS-MSSI, unlike 
MSSI, can only be used to give a description of the accumulated disease burden (Whybra et 
al., 2006). MSSI and FOS-MSSI median sub-scores were respectively 7.5 and 7.5 (general), 
10.0 and 6.0 (neurological), 2.5 and 2.0 (cardiovascular), and 4.0 and 4.0 (renal). Among our 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
9 
 
cohort, 5/12 patients (III-6, family 1, II-3 and II-5, family 2, III-2, family 3, and I-1, family 5) 
had normal cardiovascular functions (cardiovascular sub-score = 0), while patient I-1 from 
family 2 scored the maximum values for the cardiovascular sub-scores (20 in MSSI and 18 in 
FOS-MSSI). In the other 6 patients cardiovascular sub-sores were in the range 2-11 (MSSI) 
and 1-13 (FOS-MSSI). In all patients renal sub-scores contributed the least to the overall 
scores, with the highest value of 8/18 only in patient II-3, family 1. Six patients had mild 
(4/18) and five had no (0/18) renal involvement. DS3 scores ranged from 1.6 to 15.3. 
As all three severity scores used in our analysis positively correlate with age (here, correlation 
coefficients were 0.885, 0.882, and 0.835 for MSSI, FOS-MSSI, and DS3, respectively), an 
equation based on age and gender was applied to calculate the age-adjusted severity score 
(Hughes et al., 2010) (Table 2). Only the youngest patient in the studied cohort (III-6, family 
1) had its value of 0, indicating disease expression convergent with her age. In the other 
eleven patients, age-adjusted severity scores took positive values (from 2.2 to 25.5), implying 
that their phenotypes were more severe than expected for their age. Significant correlation of 
age-adjusted severity score with age was noticed (r=0.742). 
3.2. Genotype analysis 
All mutations identified in this study are characterized in Table 3. Our genetic analysis 
confirmed heterozygous change in the GLA gene in all females from families 1 and 2, in one 
female from family 4, and one from family 5. Screening for mutations in females from family 
3 revealed a novel mutation c.1055_1056delCT in exon 7 (not registered in http://fabry-
database.org, 2017/04/10 ver.3.0.7) present in patient II-1 and III-2. Concurrently it was also 
identified by independent commercial laboratories in hemizygous male patients from this 
family. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
10 
 
Mutations found in families 1-4 create early stop codons resulting in a truncated protein, 
while a mutation found in family 5 eliminates a stop codon resulting in an abnormally long 
protein (448 amino acids instead of 429). 
3.3. X-chromosome inactivation 
Eleven of twelve analyzed Fabry females were informative for the HUMARA locus 
polymorphism. In ten of them, random XCI pattern (ranging from 50:50 to 65:35) was found, 
while one, second youngest female in our cohort (III-2, family 3) was identified with slightly 
skewed XCI favoring expression of maternal chromosome bearing the mutated GLA allele 
(Table 2). XCI pattern did neither correlate with Fabry disease severity scores and sub-scores 
nor with patient’s age. 
 
4. Discussion 
Fabry disease female patients may display much variability in disease onset, severity, and 
progression (Lenders et al., 2016), which was also observed in this analysis. Our patients 
presented with all three forms of severity (mild to severe) and suffered a range of Fabry-
related manifestations including acroparasthesia, which was the most common and the earliest 
presenting symptom. Despite a small number of patients in our study, distributions of ages at 
onset of first Fabry symptoms and diagnosis were consistent with larger study encompassing 
patients enrolled in the Fabry Registry (Eng et al., 2007; Germain, 2010). It is worth 
mentioning that all female patients presented in this study were diagnosed after Fabry disease 
was recognized in the male members of their families, what highlights the importance of 
pedigree analysis as a useful tool to detect relatives (particularly females) at risk for Fabry 
disease (Gutiérrez-Amavizca et al., 2014). 
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In the past, Fabry disease was considered to be transmitted as an X-linked recessive trait. 
When it was found that heterozygous females may be affected in the same manner as 
hemizygous males, the disease was postulated to be classified as X-linked dominant (Whybra 
et al., 2001) or X-linked semi-dominant (Elstein et al., 2012), however following the 
recommendations of Dobyns (Dobyns et al., 2004), we prefer to simply describe it as X-
linked. 
The severity and progression of Fabry disease female patients in this study was evaluated by 
the MSSI, FOS-MSSI, and DS3 scoring systems. As they all correlate with age, an age-
adjusted scoring system was applied to calculate age-adjusted severity scores. It appeared that 
scores predicted by this model in our cohort also correlated with age, making comparison of 
patients severity regardless of age impossible. This may be explained by the fact that the 
system of severity score correction does not take mutation type into account. In our patients, 
cells with the mutated X chromosome (carrying either nonsense or frameshift mutation) were 
deprived of the mitigating effect of residual enzyme activity present in cells of patients with 
missense mutation. It suggests that not only age and gender but also mutation type or residual 
enzyme activity be considered in adjusting severity score in Fabry disease patients. 
The selection pressure for or against cells carrying an X-linked mutation was reported for 
several X-linked disorders (Gribnau and Barakat 2017, submitted). Skewed X-inactivation 
favoring the mutant GLA allele was also postulated to elucidate the frequent expression of 
Fabry disease manifestations in females. In the present study, all but one patient showed 
random X-chromosome inactivation, irrespective of the disease severity. Moreover, in three 
females with the highest MSSI, FOS-MSSI, and DS3 scores of 40-47, 36.5-37.5, and 14.3-
15.3, respectively (II-1, II-3, family 1, and I-1, family 2), XCI patterns were in the range of 
51:49 to 59:41, while the only patient with a slightly skewed XCI pattern of 75:25 with 
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preferential inactivation of the chromosome with the wild-type GLA allele (III-2, family3) had 
a relatively low disease severity scores (6, 5, and 2). This is at odds with the expectation of 
pronounced skewing of X-inactivation in more severely affected heterozygotes and any 
selection of cells carrying mutation. 
Several studies have undertaken XCI analysis in Fabry disease heterozygotes. Redonnet-
Vernhet et al. (Redonnet-Vernhet et al., 1996) described 26-year-old female monozygotic 
twins heterozygous for Fabry disease, one clinically affected and the other asymptomatic. 
Completely opposite skewed XCI patterns (0:100 and 97:3) were found in their fibroblasts 
which seemed to explain the observed phenotypic discordance between the twin sisters. 
Similarly, in 4 Fabry disease carriers from the Italian family skewed XCI pattern in favor of 
the mutant allele was detected in two manifesting females while the opposite XCI pattern was 
found in two asymptomatic ones, suggesting a correlation between the clinical phenotype and 
X-inactivation (Morrone et al., 2003). Another study supporting XCI contribution to the 
morbidity of Fabry disease heterozygotes was conducted in 38 Czech and Slovak female 
patients (Dobrovolny et al., 2005). Skewed XCI ratio was detected in 11 of them (in 10 the 
wild type allele was preferentially inactivated), including six females under 30 with only 
minor clinical symptoms, four aged 42-57 with MSSI scores of 38-54, indicating moderate 
and severe phenotype, and one 59-year-old woman with preferential inactivation of the 
mutated allele and MSSI score of 16 (mild phenotype). The authors observed that 
heterozygotes with the inactivated wild type allele tended to deteriorate faster than 
heterozygotes with random XCI and suggested a strong influence of X-inactivation on the 
clinical phenotypes of Fabry female patients (Dobrovolny et al., 2005), although 27 
heterozygotes (71%) without XCI skewing presented with the full spectrum of Fabry disease 
severity. Interestingly, the same proportion of Fabry heterozygotes with random XCI was 
reported in other studies: 55/77 (Elstein et al., 2012) and 39/55 (Echevarria et al., 2016). 
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Maier and coworkers (Maier et al., 2006), who defined random XCI as a ratio of between 
50:50 and 64:36, found 13/28 (46%) symptomatic Fabry disease females with random XCI, 
however using the cut-off ratio of 75:25, which was applied in the other studies, this number 
would increase to 18/28 (64%). An analogous distribution of X-inactivation patterns was 
observed in the age-matched controls (Maier et al., 2006) as well as general female population 
(Amos-Landgraf et al., 2006). In our cohort 10/11 (91%) patients had a random XCI pattern, 
meaning that the incidence of XCI skewing (1/11) did not exceed the average for either 
healthy nor Fabry disease females. 
In the presented analysis clinical involvement of female Fabry disease patients did not 
correlate with XCI profiles. This is consistent with the results presented by Maier et al. (Maier 
et al., 2006) and Elstein et al. (Elstein et al., 2012). Yet, most recent research showed that in 
females with skewed XCI, Fabry disease progression correlated with the direction of skewing 
(Echevarria et al., 2016). We have not noted that probably due to the limited number of 
patients and only one patient with the skewed XCI. Our female Fabry disease heterozygotes 
presented with the wide range of clinical severity. This phenotypic variability cannot be 
explained by the phenomenon of XCI, as in most of our patients the random XCI pattern was 
detected. 
The limitation of our study is that the X-inactivation assay was carried out on genomic DNA 
extracted from saliva samples only. DNA isolated from saliva comes admittedly from two 
sources: buccal epithelial and white blood cells, with the later contributing up to 74% (Thiede 
et al., 2000), nonetheless its analysis does not detect intertissue variation. In most females 
there is a significant association of the XCI ratios between easily obtainable tissues 
(Echevarria et al., 2016; Sharp et al., 2000). Fabry disease is a multiorgan disorder with 
serious renal, cardiac, and cerebrovascular involvement so a survey of tissue-specific XCI 
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patterns in the affected organs would give the best perspective on the contribution of XCI 
phenomenon to the clinical variability in female patients. Though such analysis would require 
invasive biopsies. On the basis of our findings, skewed X-inactivation patterns in saliva 
samples do not explain different rates of penetrance and expressivity in females with Fabry 
disease.  
Several other factors have been discussed to influence the phenotypic expression of Fabry 
disease in females but none was crucial. The nature of the mutation seems important in 
disease progression in males but in females the presence of a nonsense or missense mutation 
does not appear to affect the heterogeneous clinical picture (Lenders et al., 2016). Our results 
confirm this observation, as patients analyzed here carried either nonsense or frameshift 
mutations. Measurement of α-GAL A enzyme activity is used to distinguish classic from 
atypical Fabry disease in males but in females this parameter is unreliable even for 
identification of heterozygotes (Mehta and Hughes, 2002; Pasqualim et al., 2014), not to 
mention prediction of the disease severity. Since deacylated Gb3, globotriaosylsphingosine 
(lyso-Gb3), was reported to be dramatically increased in plasma of classically affected male 
Fabry patients (Aerts et al., 2008), there have been some successful attempts to use it as a 
prognostic marker to elucidate disease severity and progression in males. It is considered a 
potential biomarker that may improve initial diagnose of clinically relevant Fabry disease, 
particularly in females (Nowak et al., 2017). Nonetheless lyso-Gb3 levels are difficult to 
correlate with disease burden and progression in female patients (Lenders et al., 2016), 
especially that in the later-onset heterozygotes, the lysoGb3 levels may be very low or normal 
(Nowak et al., 2017). Further investigations are needed to elucidate the reason for variable 
clinical expression of Fabry disease in females. 
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Table 1. The age at diagnosis and first symptoms. 
Family Patient 
symbol 
Age at first 
symptoms 
(years) 
Age at 
diagnosis 
(years) 
First signs and symptoms reported by patients 
1 II-1 10 47 severe pain in the extremities, increased body temperature, no weight gain for several years, 
abdominal pain, fatigue, arrhythmia 
1 II-3 17 45 pain in the feet and toes, chronic proteinuria 
1 II-5 9 36 episodes of fainting, arrhythmia, supraventricular tachycardia, pain in the hands and feet 
1 III-6 9 7 hypohidrosis, poor tolerance of high temperature, headache 
2 I-1 24 53 cardiac disease, hypertension, endocrine dysfunction 
2 II-1 7 22 burning pain in the distal extremities triggered by increased temperature or fatigue 
2 II-3 10 27 burning pain in the distal extremities triggered by increased temperature or fatigue 
2 II-5 5 13 pain in the fingers and toes associated with fatigue or fever 
3 II-1 7 17 burning pain in the hands and feet 
3 III-2 8 1 burning pain in the hands and feet 
4 I-1 26 51 not specified 
5 I-1 35 45 swelling of the legs, fatigue, dyspnea, arrhythmia 
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Table 2. Severity scores and X-chromosome inactivation patterns. 
Family Patient 
symbol 
MSSI scorea FOS-MSSI scoreb Age- and 
sex- adjusted 
scorec 
DS3d XCI 
(saliva) G N C/V R Total severity G N C/V R Total severity 
1 II-1 14 16 10 0 40 moderate 13,5 12 12 0 37.5 moderate 25.5 15.3 51:49 
1 II-3 11 15 9 8 43 severe 10,5 9 9 8 36.5 moderate 25.2 14.3 59:41 
1 II-5 6 9 8 4 27 moderate 6 6 8 4 24.0 moderate 15.5 8.7 50:50 
1 III-6 2 1 0 0 3 mild 2 0 0 0 2.0 mild 0.0 1.6 56:44 
2 I-1 13 10 20 4 47 severe 11,5 3 18 4 36.5 moderate 19.6 14.6 57:43 
2 II-1 13 10 2 4 29 moderate 13,5 6 1 4 24.5 moderate 14.8 8.0 63:37 
2 II-3 4 13 0 4 21 moderate 4,5 8 0 4 16.5 mild 8.9 4.3 65:35 
2 II-5 8 11 0 4 23 moderate 8 6 0 4 18.0 mild 13.1 6.7 54:46 
3 II-1 4 10 3 4 21 moderate 4 7 3 4 18.0 mild 9.2 5.0 54:46 
3 III-2 1 5 0 0 6 mild 1 4 0 0 5.0 mild 2.2 2.0 75:25 
4 I-1 7 10 11 0 28 moderate 7 9 13 0 29.0 moderate 16.7 7.3 62:38 
5 I-1 11 7 0 0 18 mild 9 6 0 0 15.0 mild 4.4 9.6 nd 
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a The total MSSI score consists of general (G), neurological (N), cardiovascular (C/V), and renal (R) sub-scores with the maximum values of 18, 
20, 20, and 18 respectively; based on MSSI scores, clinical phenotypes are assessed as mild (<20), moderate (20-40) or severe (>40) (Whybra et 
al., 2004). 
b The total FOS-MSSI score consists of general (G), neurological (N), cardiovascular (C/V), and renal (R) sub-scores with the maximum values 
of 14.5, 15, 18, and 18 respectively; based on FOS-MSSI scores, clinical phenotypes are assessed as mild (≤ 18), moderate (19–38) or severe (> 
38) (Whybra et al., 2006). 
c Age-adjusted score is calculated by subtraction of predicted FOS-MSSI score (model equation for females: [0.96+(0.05*Age)2]) from the actual 
observed FOS-MSSI score; positive values indicate more severe phenotype and negative values - milder phenotype as average phenotype in age-
matched Fabry disease population (Hughes et al., 2010). 
d Fabry disease severity scoring system (DS3) consists of four clinical domains: peripheral nervous system, renal, cardiac and central nervous 
system plus patient reported domain; the score may range from “minimal severity=0” to “maximal severity=32” (Giannini et al., 2010). 
nd – XCI ration not determined due to homozygosity in HUMARA locus
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Table 3. Characteristics of GLA gene mutations detected in five analyzed families with 
history of Fabry disease. 
 
Family Gene mutation Location Protein change Reference 
1 c.71G>A exon 1 p.Trp24Ter (Buda et al., 2012) 
2 c.803_806delTAGT exon 6 p.Leu268Ter (Lee et al., 2000) 
3 c.1055_1056delCT exon 7 p.Ala352AspfsTer22 this work 
4 c.1057_1058delAT exon 7 p.Met353AspfsTer21 (Eng et al., 1997) 
5 c.1235_1236delCT exon 7 p.Thr412SerfsTer38 (Blaydon et al., 2001) 
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Fig. 1. 
Pedigrees of the families reported in this study; b- year of birth, d- year of death (II-3, family 
1) or age at death (I-1, family 1), XCI- X-chromosome inactivation pattern, nt- not tested, nd- 
not determined. 
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Highlights 
 Fabry disease severity in Polish female patients was assessed 
 Effect of X-chromosome inactivation (XCI) pattern on disease severity was estimated 
 Patients presented with the broad range of disease expression - from mild to severe 
 Clinical involvement did not correlate with XCI profiles 
 XCI is not a main factor in the phenotype variability of Fabry disease in females 
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